Holen Sie sich die Stockscreener-App
27.82
9.08%
-2.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$30.60
Offen:
$30.6
24-Stunden-Volumen:
3.06M
Relative Volume:
1.51
Marktkapitalisierung:
$2.49B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-13.64
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
-6.36%
1M Leistung:
-4.43%
6M Leistung:
+54.13%
1J Leistung:
+17.28%
1-Tages-Spanne:
$27.25
$31.44
1-Wochen-Bereich:
$27.25
$31.44
52-Wochen-Spanne:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
27.82 | 2.74B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
How liquid is Travere Therapeutics Inc. stockJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 7.9%Should You Sell? - MarketBeat
CEO Change: Will Travere Therapeutics Inc. stock benefit from green energy trends2025 Performance Recap & High Return Trade Opportunity Guides - mfd.ru
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? - Yahoo! Finance Canada
Is Travere Therapeutics Inc. stock heavily shortedJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - mfd.ru
Published on: 2026-02-12 19:23:57 - baoquankhu1.vn
Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Travere Therapeutics at Guggenheim Summit: Confident in Strategic Path By Investing.com - Investing.com Canada
What’s the analyst consensus on Travere Therapeutics Inc.July 2025 Trade Ideas & Safe Swing Trade Setups - mfd.ru
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
161,988 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Essex Investment Management Co. LLC - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unveiling a 40.86% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Travere Therapeutics, Inc. $TVTX Shares Sold by Federated Hermes Inc. - MarketBeat
Penserra Capital Management LLC Buys Shares of 80,556 Travere Therapeutics, Inc. $TVTX - MarketBeat
Market Review: Is Travere Therapeutics Inc trading at a discountWeekly Trade Analysis & Low Risk Entry Point Guides - baoquankhu1.vn
Piper Sandler Raises Price Target for TVTX to $38.00 | TVTX Stoc - GuruFocus
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 1,745 Shares of Stock - MarketBeat
Technical Reactions to TVTX Trends in Macro Strategies - Stock Traders Daily
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $57,301.59 in Stock - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 100,087 Shares - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $234,797.20 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 7,242 Shares of Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 4,333 Shares of Stock - MarketBeat
William Rote Sells 12,446 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $230,461.00 in Stock - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? - Yahoo Finance
Published on: 2026-02-01 07:00:12 - baoquankhu1.vn
Lisanti Capital Growth LLC Invests $3.10 Million in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
Hussman Strategic Advisors Inc. Has $1 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - The Malaysian Reserve
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Laun - GuruFocus
Travere therapeutics CEO Dube sells $1.8 million in TVTX stock By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ:TVTX) CEO Sells $244,131.35 in Stock - MarketBeat
Travere Therapeutics (TVTX) Stock Analysis: Exploring a 40% Upside in Rare Disease Biotechnology - DirectorsTalk Interviews
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Universal Beteiligungs und Servicegesellschaft mbH Boosts Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
BofA remains positive on Travere despite FDA decision delay for Filspari - MSN
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Trading the Move, Not the Narrative: (TVTX) Edition - Stock Traders Daily
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics - intellectia.ai
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Benign Growth For Travere Therapeutics, Inc. (NASDAQ:TVTX) Underpins Stock's 27% Plummet - simplywall.st
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX) - The Globe and Mail
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
32.19 |
1,745 |
56,168 |
111,226 |
| REED ELIZABETH E | Chief Legal Officer and GC |
Feb 04 '26 |
Sale |
32.18 |
2,994 |
96,359 |
105,211 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):